Novel Antibody-Drug Conjugate Demonstrates Durable Responses in Patients With Platinum-Resistant Ovarian Cancer

An investigational antibody-drug conjugate demonstrated clinically meaningful and durable responses in patients with platinum-resistant ovarian cancer, including patients whose tumors had low or no expression of folate receptor alpha (FRalpha), according to findings from the Phase 1/2 RAINFOL-01 clinical trial.

By
October 8, 2026
4 min

Dana-Farber

1

In the phase 1/2 RAINFOL-01 trial, 109 patients with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer received investigational rinatabart sesutecan.
2

Rinatabart sesutecan produced a confirmed objective response in 45.9% of patients, including 5 complete responses.
3

Median duration of response was 12.1 months, 51% of responders remained in response at 1 year, and median progression-free survival was 9.5 months.
4

Antitumor activity was observed across FRα expression levels, including in patients with low or no expression, and regardless of prior mirvetuximab treatment.
5

Common adverse events included fatigue, gastrointestinal symptoms, anemia, neutropenia, and thrombocytopenia; treatment-related adverse events led to discontinuation in 1.8% of patients.

Novel Antibody-Drug Conjugate Demonstrates Durable Responses in Patients With Platinum-Resistant Ovarian Cancer

1

2

3

4

5

Original Source(s)

Novel Antibody-Drug Conjugate Demonstrates Durable Responses in Patients With Platinum-Resistant Ovarian Cancer

Related Content

Increased Risk of Subsequent Cancers in Patients With Sézary Syndrome

Mailed Fecal Immunochemical Tests—From Efficacy to Implementation

The Evidence-Based Cancer Control Programs website – a strategy for disseminating effective interventions